循环肿瘤细胞/微栓与肿瘤标志物 CEA/CA19-9 协同考虑预测转移性结直肠癌患者的高复发预后。

Highly Correlated Recurrence Prognosis in Patients with Metastatic Colorectal Cancer by Synergistic Consideration of Circulating Tumor Cells/Microemboli and Tumor Markers CEA/CA19-9.

机构信息

Department of Engineering and System Science, National Tsing Hua University, Hsinchu 30013, Taiwan.

Molecular Medicine Research Center, Chang Gung University, Taoyuan 33302, Taiwan.

出版信息

Cells. 2021 May 10;10(5):1149. doi: 10.3390/cells10051149.

DOI:10.3390/cells10051149

PMID:34068719

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8151024/

Abstract

Circulation tumor cells (CTCs) play an important role in metastasis and highly correlate with cancer progression; thus, CTCs could be considered as a powerful diagnosis tool. Our previous studies showed that the number of CTCs could be utilized for recurrence prediction in colorectal cancer (CRC); however, the odds ratio was still lower than five. To improve prognosis in CRC patients, we analyzed CTC clusters/microemboli, CTC numbers, and carcinoembryonic antigen (CEA)/carbohydrate antigen 19-9 (CA19-9) levels using a self-assembled cell array (SACA) chip system for recurrence prediction. In CRC patients, the presence of CTC clusters/microemboli may have higher correlation in metastasis when compared to the high number of CTCs. Additionally, when both the number of CTCs and serum CEA levels are high, very high odds ratios of 24.4 and 17.1 are observed in patients at all stages and stage III of CRC, respectively. The high number of CTCs and CTC clusters/microemboli simultaneously suggests the high chance of relapse (odds ratio 8.4). Overall, the characteristic of CTC clusters/microemboli, CEA level, and CTC number have a clinical potential to enhance CRC prognosis.

摘要

循环肿瘤细胞（CTCs）在转移中起重要作用，与癌症进展高度相关；因此，CTCs 可以被视为一种强大的诊断工具。我们之前的研究表明，CTCs 的数量可用于结直肠癌（CRC）的复发预测；然而，优势比仍低于五。为了改善 CRC 患者的预后，我们使用自行组装的细胞阵列（SACA）芯片系统分析了 CTC 簇/微栓子、CTC 数量和癌胚抗原（CEA）/糖类抗原 19-9（CA19-9）水平，以进行复发预测。在 CRC 患者中，与高数量的 CTC 相比，CTC 簇/微栓子的存在可能与转移具有更高的相关性。此外，当 CTC 数量和血清 CEA 水平都高时，在所有阶段和 III 期 CRC 患者中，优势比分别为 24.4 和 17.1。大量的 CTC 及其簇/微栓子同时提示复发的高几率（优势比 8.4）。总的来说，CTC 簇/微栓子、CEA 水平和 CTC 数量的特征具有增强 CRC 预后的临床潜力。